WO2022265264A1 - B형 간염바이러스 pres1항원의 간세포 수용체 결합부위에 특이적으로 결합하는 인간 항체 및 이의 용도 - Google Patents
B형 간염바이러스 pres1항원의 간세포 수용체 결합부위에 특이적으로 결합하는 인간 항체 및 이의 용도 Download PDFInfo
- Publication number
- WO2022265264A1 WO2022265264A1 PCT/KR2022/007679 KR2022007679W WO2022265264A1 WO 2022265264 A1 WO2022265264 A1 WO 2022265264A1 KR 2022007679 W KR2022007679 W KR 2022007679W WO 2022265264 A1 WO2022265264 A1 WO 2022265264A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- seq
- hbv
- pres1
- antigen
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title claims abstract description 131
- 102000036639 antigens Human genes 0.000 title claims abstract description 113
- 108091007433 antigens Proteins 0.000 title claims abstract description 113
- 239000000427 antigen Substances 0.000 title claims abstract description 110
- 230000027455 binding Effects 0.000 title abstract description 98
- 241000282414 Homo sapiens Species 0.000 title description 35
- 210000003494 hepatocyte Anatomy 0.000 title description 16
- 208000015181 infectious disease Diseases 0.000 claims abstract description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 37
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 235000018102 proteins Nutrition 0.000 claims description 22
- 235000004279 alanine Nutrition 0.000 claims description 18
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 208000002672 hepatitis B Diseases 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 10
- 108010032595 Antibody Binding Sites Proteins 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 abstract description 26
- 108020003175 receptors Proteins 0.000 abstract description 26
- 238000006386 neutralization reaction Methods 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 51
- 238000002965 ELISA Methods 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 239000002245 particle Substances 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 238000004091 panning Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 230000003472 neutralizing effect Effects 0.000 description 9
- 238000002823 phage display Methods 0.000 description 9
- 241000285366 HBV genotype D Species 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000013613 expression plasmid Substances 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102100031673 Corneodesmosin Human genes 0.000 description 6
- 101710139375 Corneodesmosin Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 108010003524 sodium-bile acid cotransporter Proteins 0.000 description 5
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 3
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000285387 HBV genotype A Species 0.000 description 3
- 241000285424 HBV genotype C Species 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 101150010882 S gene Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 238000012867 alanine scanning Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000012575 bio-layer interferometry Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 229940060415 hepatitis b immune globulin Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102220614803 Calmodulin-3_Y92A_mutation Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102220521681 Insulin-induced gene 1 protein_S94A_mutation Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102220514646 Lysophospholipid acyltransferase 5_I96A_mutation Human genes 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 102220537824 Nebulette_S99A_mutation Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 2
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 2
- 102220482069 Nuclear cap-binding protein subunit 2_F25A_mutation Human genes 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102220491416 Protein phosphatase 1 regulatory subunit 12C_S91A_mutation Human genes 0.000 description 2
- 102220474279 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform_Y97A_mutation Human genes 0.000 description 2
- 102220468330 Tektin-1_Y96A_mutation Human genes 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 102220352372 c.148T>G Human genes 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000002848 electrochemical method Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 102220004414 rs104894504 Human genes 0.000 description 2
- 102220280441 rs776730435 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical class O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 101150098636 A30L gene Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 229940122800 HBV entry inhibitor Drugs 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101710084021 Large envelope protein Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102220604320 Suppressor of cytokine signaling 4_L22A_mutation Human genes 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- -1 aromatics Substances 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000004057 biotinyl group Chemical class [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 102220417868 c.98C>G Human genes 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102220541939 pre-mRNA 3' end processing protein WDR33_A33S_mutation Human genes 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 102200127443 rs121918005 Human genes 0.000 description 1
- 102200082820 rs33960931 Human genes 0.000 description 1
- 102220023073 rs387907411 Human genes 0.000 description 1
- 102200128614 rs397508220 Human genes 0.000 description 1
- 102220045877 rs587782465 Human genes 0.000 description 1
- 102200015515 rs797045155 Human genes 0.000 description 1
- 102200153318 rs913934445 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000024058 virion binding Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5764—Hepatitis B surface antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to a human antibody that specifically binds to a hepatocyte receptor binding site of hepatitis B virus preS1 antigen and uses thereof.
- HBV infection is one of the most serious and widespread public health problems. In 2016, there were about 290 million people chronically infected with HBV worldwide.
- Genotypes A and D are distributed in Africa and Europe, genotypes B and C are mainly distributed in Asia, and genotypes E-J often appear in Europe, America and Asia.
- the most prevalent genotypes are A-D, accounting for about 90% of hepatitis B cases.
- the HBV envelope contains three structurally related proteins: S (small), M (middle) and L (Large).
- S protein is the most abundant protein among these envelope proteins.
- M protein is composed of preS2 and S
- L protein is composed of preS1, preS2, and S.
- Hepatocytes infected with HBV produce infectious HBV particles as well as non-infectious spherical and filamentous subviral particles. These quasiviral particles are composed mostly of the S protein and are typically produced 1000 to 10000 times more than virions. These subviral particles are presumed to reduce the virus-specific immune response.
- the preS1 of the L protein is mainly present in infectious virions.
- amino acids 20-26 of preS1 (A-C, F genotype; 9-15 for D genotype; 19-25 for E genotype) bind to the hepatocyte receptor NTCP (sodium taurocholate cotransporting polypeptide) to prevent HBV infection.
- NTCP sodium taurocholate cotransporting polypeptide
- Hepatitis B immune globulin is used for preventive medical treatment after accidental or perinatal exposure to HBV.
- HBIG is prepared by collecting serum with high anti-S protein antibody titers.
- mAb monoclonal antibody
- A-C human monoclonal antibody
- A-C F genotypes
- amino acids 31-38 A-C, F genotypes
- amino acids 20-26, A-C, F genotypes amino acids 20-26, A-C, F genotypes
- mice immunized with HBV particles or recombinant preS1 antigen have been prepared from mice immunized with HBV particles or recombinant preS1 antigen (Heermann K, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich W. 1984. Large surface proteins of hepatitis B virus containing the pre-s sequence.Journal of virology.52 : 396-402;Pizarro JC, Vulliez-le Normand B, Riottot MM, Budkowska A, Bentley GA.2001. Structural and functional characterization of a monoclonal antibody specific Kim JH, Gripon P, Bouezzedine F, Jeong MS, Chi SW, Ryu SE, Hong HJ.
- the present inventors have made diligent efforts to provide a monoclonal antibody that can bind to various genotypes of HBV and is specific to the hepatocyte receptor binding site of preS1 for more efficient prevention or treatment, and as a result, most of the hepatitis B virus
- the present invention was completed by developing a human monoclonal antibody that binds to all of the genotypes A to F occupied and binds to the hepatocyte receptor binding site to exhibit the efficacy of inhibiting HBV infection.
- An object of the present invention is to provide a novel antibody that specifically binds to the receptor binding site of the hepatitis B virus preS1 antigen.
- Another object of the present invention is to provide a method for producing the antibody.
- Another object of the present invention is to provide a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, and a host cell into which the vector is introduced.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating HBV infection comprising the antibody.
- Another object of the present invention is to provide a method for preventing or treating HBV infection using the antibody.
- Another object of the present invention is a method for providing information for diagnosis of HBV infection, comprising the step of detecting preS1 present in a biological sample isolated from an individual suspected of HBV infection through an antigen-antibody reaction using the antibody. is to provide
- Another object of the present invention is to provide a composition for detecting HBV, comprising the antibody.
- Another object of the present invention is to provide a kit for detecting HBV comprising the antibody.
- the antibody of the present invention targets sequences shared by various genotypes of HBV, can bind to various genotypes of HBV, and has excellent binding ability with HBV, so it can be useful not only for detection and diagnosis of HBV infection but also for fields requiring treatment.
- HBV preS1 N-terminal amino acid sequences (genotypes A-F, numbered according to HBV genotype A).
- Amino acids 20-26 are essential receptor-binding motifs of preS1 and are indicated in gray shading. Sequences included in the Bio-preS1-L peptide are underlined.
- Figure 2 shows the experimental results of isolating the anti-preS1 monoclonal Fab from the human Fab synthetic library.
- Figure 2A shows the input and output titers of phage for each round of panning. pfu represents a plaque-forming unit.
- Figure 2B shows positive polyclonal phage amplification determined by indirect ELISA. For the isolation of monoclonal Fabs, the 4th round of panning with the most amplification for preS1 was selected.
- Figure 2C shows the results of indirect ELISA of AbSO Fab phage having the highest antigen-binding activity against the bio-preS1-L peptide among the positive Fab clones selected from the output of the fourth panning.
- Figure 3 is an analysis of the antigen-binding activity of AbSO mAb converted and purified from AbSO Fab to IgG1.
- 3A shows SDS-PAGE of AbSO purified under non-reducing (NR, 6%) and reducing (R, 10%) conditions.
- M represents a protein marker
- HC represents a heavy chain
- LC represents a light chain.
- 3B shows the antigen-binding activity of purified AbSO mAb against preS1 of HBV genotypes (A-D) was evaluated by ELISA.
- 3C shows the results of affinity analysis of AbSO by BLI using Octet RED384.
- Fig. 3D shows the result of analysis by FACS that the AbSO antibody does not bind to the human ovarian cancer cell line SKOV3, which expresses L1CAM but does not express preS1, in order to exclude the possibility of non-specific binding of the AbSO antibody to preS1.
- Figure 4 is the result of evaluating the virion binding activity and in-vitro HBV neutralization activity of AbSO for HBV genotype D.
- 4A is immunoprecipitation of HBV genotype D particles by AbSO.
- HzKR127-3.2 (ref: Kim JH et al. Enhanced humanization and affinity maturation of neutralizing anti-hepatitis B virus preS1 antibody based on antigen-antibody complex structure.
- FEBS Lett. 589:193-200) was used as a positive control, and mouse IgG was used as a negative control.
- RC DNA represents relaxed circular DNA
- DSL DNA represents double-stranded linear DNA.
- Figure 4B shows HBV genotype D particles pre-incubated with AbS0 (10, 1, 0.1 ⁇ g) or mouse IgG (10 ⁇ g) and then added to cultured HepG2-NTCP cells, followed by medium every 2 days. was replaced and cells were harvested 7 days after infection. This is the result of Southern blot hybridization by extracting HBV DNA from the harvested cells.
- 5 shows the results of expression, purification, and SDS-PAGE of an alanine substitution variant of amino acids 19-34 of GST-preS1 (aa 1-56)-strep for epitope mapping of AbSO antibody.
- Figure 6 shows the results of analyzing the binding ability of the AbSO antibody to the alanine substitution variant of amino acids 19-34 of GST-preS1 (aa 1-56)-strep by indirect ELISA.
- FIG. 8 shows antibody variants in which Ala33 of HCDR1 (FIGS. 8A-C) and Ser50 of HCDR2 (FIG. 8D) are substituted with other residues in order to analyze the binding site (paratope) of AbS0 antibody to the preS1 antigen. This is the result of analyzing the antigen binding ability by indirect ELISA.
- Figure 9 is the antigen binding ability of the GST-preS1 (aa 1-56) -strep protein of Genotype A having a receptor binding motif of conservative (NPLGFFP; WT) and other sequences (NPLGFLP; preS1-L25) of AbS1 and AbS0 antibodies. This is the result of analysis by indirect ELISA.
- FIG. 10 is a result of analyzing the antigen-binding ability of AbS1 antibodies to GST-preS1 (aa 1-56)-strep protein of genotypes E and F by quantitative ELISA (FIG. 10A) and indirect ELISA (FIG. 10B).
- One aspect of the present invention for achieving the object of the present invention provides a novel antibody that specifically binds to the hepatitis B virus preS1 antigen.
- antibody refers to a protein molecule that serves as a receptor that specifically recognizes an antigen, including an immunoglobulin molecule that is immunologically reactive with a specific antigen, and includes polyclonal antibodies, monoclonal antibodies, Both whole antibodies and antibody fragments are included.
- the term also includes chimeric antibodies, humanized antibodies, human antibodies and bivalent or bispecific molecules (eg bispecific antibodies), diabodies, triabodies and tetrabodies.
- the term further includes single-chain antibodies, scabs, derivatives of antibody constant regions and artificial antibodies based on protein scaffolds that have a binding function to FcRn.
- a full antibody has a structure having two full-length light chains and two full-length heavy chains, and each light chain is connected to the heavy chain by a disulfide bond.
- the total antibody includes IgA, IgD, IgE, IgM, and IgG, and IgG, and IgG includes IgG1, IgG2, IgG3, and IgG4 as subtypes.
- the antibody fragment refers to a fragment having an antigen-binding function, and includes Fd, Fab, Fab', F(ab') 2 and Fv.
- the Fd refers to the heavy chain part included in the Fab fragment.
- the Fab has a structure having light and heavy chain variable regions, a light chain constant region, and a first constant region (CH1 domain) of a heavy chain, and has one antigen binding site.
- Fab' is different from Fab in that it has a hinge region containing one or more cysteine residues at the C-terminus of the heavy chain CH1 domain.
- An F(ab') 2 antibody is produced by forming a disulfide bond between cysteine residues in the hinge region of Fab'.
- Fv means a minimum antibody fragment having only the heavy chain variable region and the light chain variable region.
- double disulfide Fv dsFv
- the heavy chain variable region and the light chain variable region are linked by a disulfide bond
- scFv short chain Fv
- the heavy chain variable region and the light chain variable region are generally covalently linked through a peptide linker.
- Such antibody fragments can be obtained using proteolytic enzymes (for example, Fab can be obtained by restriction digestion of whole antibodies with papain, and F(ab') 2 fragments can be obtained by digestion with pepsin), specifically It can be produced through genetic recombination technology.
- Antibodies of the present invention may be monoclonal antibodies.
- the term "monoclonal antibody” refers to an antibody molecule of a single molecular composition obtained from substantially the same antibody population, and such a monoclonal antibody exhibits a single binding specificity and affinity for a specific epitope.
- an immunoglobulin has a heavy chain and a light chain, each comprising a constant region and a variable region (the regions are also known as domains).
- the variable regions of the light and heavy chains include three variable regions called complementarity-determining regions (hereinafter referred to as "CDRs") and four framework regions.
- CDRs complementarity-determining regions
- the CDR mainly serves to bind to an antigenic epitope.
- the CDRs of each chain are typically called CDR1, CDR2, CDR3 sequentially starting from the N-terminus, and are also identified by the chain in which a particular CDR is located.
- Antibodies of the present invention may be human antibodies.
- human antibody is a molecule derived from human immunoglobulin, and means that all amino acid sequences constituting the antibody, including complementarity determining regions and structural regions, are composed of human immunoglobulin amino acid sequences.
- Human antibodies are commonly used in the treatment of human diseases, which may have at least three potential advantages. First, it interacts better with the human immune system, eg complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) As a result, target cells can be destroyed more efficiently. Second, there is an advantage that the human immune system does not recognize the antibody as foreign. Thirdly, there is an advantage that the half-life in the human circulation is similar to that of naturally occurring antibodies even when the drug is administered in a smaller amount and less frequently.
- the antibody of the present invention as described above includes a constant region, it may include a constant region derived from IgG, IgA, IgD, IgE, IgM, a combination thereof, or a hybrid thereof. .
- dimers or multimers may be formed from two or more constant regions selected from the group consisting of IgG, IgA, IgD, IgE and IgM constant regions.
- hybrid means that sequences corresponding to immunoglobulin heavy chain constant regions of two or more different origins exist within a single chain immunoglobulin heavy chain constant region, and examples include IgG, IgA, IgD, and IgE. And hybrids of domains consisting of 1 to 4 domains selected from the group consisting of CH1, CH2, CH3 and CH4 of IgM are possible.
- hepatitis B virus is a term used interchangeably with HBV, and is a virus that can cause hepatitis B due to an immune response to it when infected.
- preS1 antigen refers to a protein encoded by one S gene among the four S, C, X, and P genes of HBV DNA.
- the S gene is a gene that encodes a surface antigen, and a Pre-S region exists in front of it, and Pre-S is divided into a PreS1 region and a PreS2 region.
- Surface proteins such as S (small) protein, M (middle) protein, and L (large) protein are coded by these.
- the S protein is encoded by the S gene, the M protein is composed of preS2 and S proteins, and the L protein is composed of preS1, preS2, and S proteins and is mainly present in infectious virus particles (virions). Therefore, preS1 constitutes a viral surface protein and is mainly present in infectious virions.
- Antibodies provided in the present invention can bind to HBV of various genotypes, specifically, may be capable of binding to all of genotypes A, B, C, D, E and F.
- the antibody provided in the present invention may bind to a receptor binding motif sequence shared by genotypes A, B, C, D, E and F of preS1, but is not limited thereto.
- antibody that binds to the hepatitis B virus preS1 antigen refers to an antibody that can exhibit HBV neutralization activity and/or HBV infection inhibitory activity by binding to preS1, a surface antigen of HBV.
- the antibody provided in the present invention may bind to an amino acid at a specific position of the preS1 antigen, and the position may be a position corresponding to positions 22, 23, and 25 based on SEQ ID NO: 19 .
- SEQ ID NO: 19 is only a reference sequence for specifying the binding position of the antibody of the present invention in any preS1 antigen, and the preS1 antigen of the present invention is not limited to SEQ ID NO: 19, and any preS1 antigen protein
- positions corresponding to positions 22, 23, and 25 based on SEQ ID NO: 19 can be identified through sequence alignment.
- sequence alignment a Needleman-Wunsch algorithm known in the art, a Needle program of the EMBOSS package, multiple sequence alignment, etc. may be used, but is not limited thereto.
- the amino acid sequence of the preS1 antigen can be obtained from a known database, and may include, for example, SEQ ID NO: 17 or 18.
- the amino acids at positions 22, 23, and 25 may be amino acids represented by positions 3, 4, and 6, respectively, in the amino acid sequence of SEQ ID NO: 17 or 18. However, it is not limited thereto.
- amino acids 22, 23, and 25 are binding sites of the antibody of the present invention, and the "epitope" of the preS1 antigen recognized by the antibody of the present invention is based on SEQ ID NO: 19. It can be expressed as positions corresponding to No. 22, No. 23 and No. 25 as . Meanwhile, positions corresponding to positions 22, 23, and 25 based on SEQ ID NO: 19 may be included in the site where the preS1 antigen binds to the hepatocyte receptor. Therefore, the antibodies of the present invention can inhibit the action of preS1 antigen binding to hepatocyte receptors.
- the antibody is leucine (Leu22) corresponding to position 22 based on SEQ ID NO: 19, glycine (Gly23) corresponding to position 23 and position corresponding to position 25 It may bind to phenylalanine (Phe25) or leucine (Leu25).
- the antibody may be an antibody having tyrosine 8 of the LCDR3 sequence of SEQ ID NO: 5 and leucine 6 of the HCDR3 sequence of SEQ ID NO: 9 as a paratope.
- the antibody may be an antibody having amino acid No. 1 of the HCDR2 sequence represented by SEQ ID NO: 8 as a paratope.
- Amino acid No. 1 of SEQ ID NO: 8 may be alanine or leucine.
- paratope refers to a region or region on an antibody or antibody fragment where an antibody or antibody fragment specifically binds to an antigen, that is, where the antibody or antibody fragment physically contacts the antigen.
- the antibody comprises a light chain comprising a light chain CDR1 of SEQ ID NO: 3 (LCDR1), a light chain CDR2 of SEQ ID NO: 4 (LCDR2), and a light chain CDR3 of SEQ ID NO: 5 (LCDR3) variable region; and a heavy chain variable region comprising heavy chain CDR1 (HCDR1) of SEQ ID NO: 7, heavy chain CDR2 (HCDR2) of SEQ ID NO: 8, and heavy chain CDR3 (HCDR3) of SEQ ID NO: 9, an antibody that specifically binds to preS1.
- LCDR1 light chain CDR1 of SEQ ID NO: 3
- LCDR2 light chain CDR2 of SEQ ID NO: 4
- LCDR3 light chain CDR3 of SEQ ID NO: 5
- the antibody comprises a light chain comprising a light chain CDR1 of SEQ ID NO: 3 (LCDR1), a light chain CDR2 of SEQ ID NO: 4 (LCDR2), and a light chain CDR3 of SEQ ID NO: 6 (LCDR3).
- variable region; And a heavy chain variable region comprising the heavy chain CDR1 (HCDR1) of SEQ ID NO: 10, the heavy chain CDR2 (HCDR2) of SEQ ID NO: 11 or 12, and the heavy chain CDR3 (HCDR3) of SEQ ID NO: 13, which binds specifically to preS1 may be an antibody.
- the light chain variable region of the antibody may be composed of the amino acid sequence described in SEQ ID NO: 1. Specifically, it may be composed of the amino acid sequence set forth in SEQ ID NO: 14, but is not limited thereto.
- the heavy chain variable region of the antibody may be composed of the amino acid sequence described in SEQ ID NO: 2. Specifically, it may be composed of the amino acid sequence described in SEQ ID NO: 15 or 16, but is not limited thereto.
- the antibody may include a light chain variable region described in SEQ ID NO: 1 and a heavy chain variable region described in SEQ ID NO: 2, but is not limited thereto.
- an antibody that specifically binds to the preS1 region including the light chain variable region of SEQ ID NO: 14 and the heavy chain variable region of SEQ ID NO: 15, was named AbS0, and AbS0 is HBV genotypes A, B, and C And it was confirmed that it exhibits excellent binding ability for all of D.
- the human antibody binding to preS1 of the present invention provides high affinity and low immunogenicity compared to conventional antibodies and exhibits excellent neutralization and infection inhibitory activity against HBV, the antibody of the present invention recognizes the antigen against preS1. Or, it can be used for any application that can be useful for neutralization of HBV, inhibition of infection.
- Another aspect of the present invention provides a method for producing the antibody.
- Antibodies of the present invention can be easily produced by known antibody production techniques. For example, methods for preparing monoclonal antibodies can be performed by preparing hybridomas using B lymphocytes obtained from immunized animals (Koeher and Milstein, 1976, Nature, 256:495), or phage display (phage display). display) technology, etc., but is not limited thereto, and can be easily prepared using other known antibody manufacturing techniques.
- methods for preparing monoclonal antibodies can be performed by preparing hybridomas using B lymphocytes obtained from immunized animals (Koeher and Milstein, 1976, Nature, 256:495), or phage display (phage display). display) technology, etc., but is not limited thereto, and can be easily prepared using other known antibody manufacturing techniques.
- An antibody library using phage display technology is a method of directly obtaining antibody genes from B lymphocytes and expressing antibodies on the surface of phage without preparing hybridomas. Using phage display technology, many existing difficulties associated with producing monoclonal antibodies by B-cell immortalization can be overcome.
- phage display technology includes: 1) inserting an oligonucleotide of random sequence into a gene region corresponding to the N-terminus of the phage coat protein pIII (or pIV); 2) expressing a fusion protein of a portion of the native envelope protein and a polypeptide encoded by the oligonucleotide of the random sequence; 3) treating a substance capable of binding to the polypeptide encoded by the oligonucleotide; 4) eluting the antibody-phage particles bound to the material using low pH or molecules with binding competence; 5) amplifying phages eluted by panning in host cells; 6) repeating the method to obtain the desired amount; and 7) determining the sequence of an antibody having activity from the DNA sequences of the phage clones selected by panning.
- the method for producing a monoclonal antibody of the present invention can be performed using phage display technology.
- phage display technology Those skilled in the art are familiar with known phage display techniques, for example Barbas et al. (METHODS: A Companion to Methods in Enzymology 2:119, 1991 and J. Virol. 2001 Jul;75(14):6692-9) and Winter et al. (Ann. Rev. Immunol.
- Phages that can be used to construct an antibody library include, for example, filamentous phages, such as fd, M13, f1, If1, Ike, Zj/Z, Ff, Xf, Pf1 or Pf3 phages, but are limited thereto it is not going to be
- vectors that can be used for the expression of heterologous genes on the surface of the filamentous phage include, for example, phage vectors such as fUSE5, fAFF1, fd-CAT1 or fdtetDOG or phagemids such as pHEN1, pComb3, pComb8 or pSEX Vectors are, but are not limited to.
- helper phages that can be used to provide wild-type envelope proteins required for successful reinfection of recombinant phages for amplification include, but are not limited to, M13K07 or VSCM13.
- Polynucleotides encoding the monoclonal antibodies or phagedisplay clones of the present invention can be readily isolated and sequenced using conventional procedures. For example, oligonucleotide primers designed to specifically amplify the heavy and light chain coding regions from the phage template DNA can be used. Once the polynucleotide has been isolated, it can be placed into an expression vector, which can then be introduced into a suitable host cell to produce the desired monoclonal antibody from the transformed host cell (i.e., transformant). .
- the method for producing the human monoclonal antibody of the present invention comprises the step of amplifying the polynucleotide encoding the human monoclonal antibody in an expression vector containing the polynucleotide encoding the human monoclonal antibody. It may be a manufacturing method of, but is not limited thereto.
- Another aspect of the present invention provides a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, and a host cell into which the vector is introduced.
- the antibody is as described above.
- the expression vector containing the polynucleotide encoding the antibody provided in the present invention is not particularly limited thereto, but is mammalian cell (eg, human, monkey, rabbit, rat, hamster, mouse cell, etc.), plant cell, yeast It can be a vector capable of replicating and / or expressing the polynucleotide in eukaryotic or prokaryotic cells, including cells, insect cells, or bacterial cells (eg, E. coli, etc.), specifically, the nucleotide in the host cell It may be a vector operably linked to an appropriate promoter for expression and containing at least one selectable marker.
- the polynucleotide may be introduced into a phage, plasmid, cosmid, mini-chromosome, virus or retroviral vector.
- the expression vector containing the polynucleotide encoding the antibody may be an expression vector containing polynucleotides encoding the heavy chain or light chain of the antibody, respectively, or an expression vector including both polynucleotides encoding the heavy chain or light chain of the antibody.
- the host cell into which the expression vector provided in the present invention is introduced is not particularly limited thereto, but is transformed into bacterial cells such as Escherichia coli, Streptomyces, and Salmonella typhimurium; yeast cells; fungal cells such as Pichia pastoris; Insect cells such as Drozophila and Spodoptera Sf9 cells; CHO (Chinese hamster ovary cells, chinese hamster ovary cells), SP2/0 (mouse myeloma), human lymphoblastoid, COS, NSO (mouse myeloma), Bowes melanoma cells, HT-1080 , animal cells such as BHK (baby hamster kidney cells), HEK (human embryonic kidney cells), and PERC.6 (human retinal cells); or plant cells.
- bacterial cells such as Escherichia coli, Streptomyces, and Salmonella typhimurium
- yeast cells fungal cells such as Pichia pastoris
- transduction refers to a method of delivering a vector containing a polynucleotide encoding the antibody to a host cell.
- introduction is performed by calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofectamine and protoplast fusion, etc. It can be performed by several methods known in the art.
- transduction means the transfer of a target into a cell using virus particles as a means of infection.
- vectors can be introduced into host cells by gene gun bombardment or the like. In the present invention, introduction may be used in combination with transformation.
- compositions for preventing or treating HBV infection comprising the antibody.
- the composition may be for preventing or treating hepatitis B.
- hepatitis B refers to a disease in which liver inflammation occurs due to an immune response caused by infection with HBV. Since the antibody of the present invention exhibits excellent neutralization and infection inhibitory effects against HBV, it can be used for the prevention or treatment of hepatitis B.
- prevention may refer to any action that suppresses or delays the onset of HBV infection by administration of the composition
- treatment means that symptoms caused by HBV infection are improved by administration of the composition. It can mean any action that becomes or is advantageously changed.
- the pharmaceutical composition may further include a pharmaceutically acceptable carrier.
- the term "pharmaceutically acceptable carrier” refers to a carrier or diluent that does not stimulate organisms and does not inhibit the biological activity and properties of the administered compound.
- Acceptable pharmaceutical carriers for compositions formulated as liquid solutions are sterile and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added if necessary.
- diluents such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets.
- the pharmaceutical composition may be in various oral or parenteral formulations. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in one or more compounds, for example, starch, calcium carbonate, sucrose or lactose ( lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories.
- Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
- a base for the suppository witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.
- the pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. It can have one formulation.
- composition of the present invention is administered in a pharmaceutically effective amount.
- the term "pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is dependent on the type and severity of the subject, age, sex, and cancer. It may be determined according to factors including type, activity of drug, sensitivity to drug, administration time, route of administration and excretion rate, duration of treatment, drugs used concurrently, and other factors well known in the medical field.
- the composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And it can be single or multiple administration. It is important to administer the amount that can obtain the maximum effect with the minimum amount without side effects in consideration of all the above factors, and can be easily determined by those skilled in the art.
- Another aspect of the present invention provides a method for preventing or treating HBV infection using the antibody.
- the method may include administering the antibody to a subject suspected of being infected with HBV.
- the method may be a method for preventing or treating HBV infection comprising administering a pharmaceutical composition further comprising an antibody and a pharmaceutically acceptable carrier to an HBV-infected or infected subject, wherein the pharmaceutically acceptable Possible carriers are the same as described above.
- the subject includes mammals including cows, pigs, sheep, chickens, dogs, humans, and the like, birds, and the like, and includes, without limitation, subjects whose HBV infection is treated by administration of the composition of the present invention.
- the antibody may be administered single or multiple times in a pharmaceutically effective amount.
- the antibody may be administered in the form of a solution, powder, aerosol, capsule, enteric-coated tablet or capsule, or suppository.
- Routes of administration include, but are not limited to, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, endothelial administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, intrarectal administration, and the like.
- the method may also be used for the prevention or treatment of hepatitis B, and specifically for the treatment of any one or more HBV infections selected from HBV genotypes A, B, C, D, E and F, but is not limited thereto. .
- Another aspect of the present invention is the use of the antibody for the manufacture of a pharmaceutical for the prevention or treatment of HBV infection.
- the medicine may also be used for the prevention or treatment of hepatitis B and for the treatment of any one or more HBV infections selected from HBV genotypes A, B, C, D, E and F, but is not limited thereto.
- the antibody and the prevention or treatment of HBV infection are as described above.
- Another aspect of the present invention is a method for providing information for diagnosis of HBV infection, comprising the step of detecting preS1 present in a biological sample isolated from an individual suspected of HBV infection through an antigen-antibody reaction using the antibody provides
- the method may be a method for diagnosing HBV infection. Also, the method can be used for diagnosis of hepatitis B.
- the antibody and HBV were as described above.
- the method for providing information for diagnosis of HBV may detect the preS1 protein by reacting the preS1-specific antibody of the present invention with a biological sample isolated from an individual suspected of having HBV infection and detecting the formation of an antigen-antibody complex, Through this, it is possible to provide information for diagnosis of HBV infection.
- detecting the preS1 protein through an antigen-antibody reaction by treating a biological sample isolated from an individual suspected of being infected with HBV with the antibody; (b) comparing the level of preS1 protein detected in (a) with a control group, and determining that the patient is HBV-infected if the level of preS1 protein is higher than that of the control group.
- biological sample includes tissues, cells, whole blood, serum, plasma, tissue autopsy samples (brain, skin, lymph nodes, spinal cord, etc.), cell culture supernatants, disrupted eukaryotic cells, bacterial expression systems, and the like. However, it is not limited thereto.
- the term "antigen-antibody complex” refers to a combination of a preS1 protein antigen in a sample and an antibody according to the present invention recognizing it, and the formation of such an antigen-antibody complex is performed by a colorimetric method or an electrochemical method. Detection by any method selected from the group consisting of electrochemical method, fluorescence method, luminometry, particle counting method, visual assessment, and scintillation counting method can do. However, it is not necessarily limited only to these, and various applications and applications are possible.
- markers can be used to detect antigen-antibody complexes.
- Specific examples may be selected from the group consisting of enzymes, fluorescent materials, ligands, luminescent materials, microparticles, and radioactive isotopes, but are not necessarily limited thereto.
- Enzymes used as detection markers include acetylcholinesterase, alkaline phosphatase, ⁇ -D-galactosidase, horseradish peroxidase, ⁇ -latamase, and the like, and fluorescent substances include fluorescein , Eu 3+ , Eu 3+ chelate or cryptate, etc., including biotin derivatives as ligands, acridinium esters, isoluminol derivatives, etc. as light-emitting substances, colloidal gold as microparticles, It includes colored latex and the like, and radioactive isotopes include, but are not limited to, 57 Co, 3 H, 125 I, 125 I-Bolton Hunter reagent, and the like.
- the detection method may be an antigen-antibody complex using enzyme immunosorbent assay (ELISA).
- Enzyme immunosorbent assay includes direct ELISA using a labeled antibody that recognizes an antigen attached to a solid support, and indirect ELISA using a labeled secondary antibody that recognizes a capture antibody in a complex of antibodies that recognize an antigen attached to a solid support.
- direct sandwich ELISA using another labeled antibody that recognizes an antigen in a complex of antibody and antigen attached to a solid support, followed by reaction with another antibody that recognizes an antigen in a complex of antibody and antigen attached to a solid support. It includes various ELISA methods such as indirect sandwich ELISA using a labeled secondary antibody that recognizes the antibody.
- the antibody may have a detection label, and when it does not have a detection label, these monoclonal antibodies can be captured and identified by treatment with another antibody having a detection label.
- Another aspect of the present invention provides a composition for detecting HBV, comprising the antibody provided in the present invention.
- the antibody is as described above.
- the HBV detection may be to detect the preS1 protein of HBV.
- the composition is a conventional method for confirming the presence or absence of an antigen protein from a biological sample using an antibody, such as a tool for collecting a test sample or applying a detection reagent, a reagent or device for confirming antigen-antibody binding, and the like. Tools, devices, or reagents included in the composition for detection of may be further included.
- kits for detecting HBV comprising the antibody.
- the HBV detection is as described above.
- the kit may also be in the form of a hepatitis diagnosis kit.
- the composition, hepatitis B, and diagnosis are as described above.
- Another aspect of the present invention is the use of the antibody for the preparation of a composition for detecting HBV.
- the antibody and HBV were as described above.
- the thus prepared recombinant preS1 antigen and Bio-preS1-L peptide were used as antigens for antibody library panning.
- the GST-preS1(1-56)-strep tag of HBV genotype AF was expressed and purified in E. coli.
- the sequence of preS1(1-56) of genotype AF is shown in FIG. 1 .
- preS1 antigens GST-preS1 (1-119), GST-preS1 (1-56), Bio-preS1-L peptide and preS1 (1-119) of Example 1, respectively, 1, 2, and 3 and 4 rounds of panning of the human synthetic Fab library (diversity 1.35 ⁇ 10 9 ) according to the standard panning procedure.
- Each preS1 antigen was coated on an immunotube (streptavidin-coated plate in the case of Bio-preS1-L peptide) and stored at 4°C overnight.
- Antibody library phages were incubated with antigen and unbound phages were washed with 0.1% PBST (0.1% Tween 20 in PBS).
- Bound phages were eluted using 10 ⁇ g/ml trypsin solution for 30 minutes at 37°C.
- E. coli TG1 cells were infected with the eluted phage, grown at 37°C for 1 hour, and incubated at 37°C overnight.
- the next round of panning was performed with the amplified phage, and the degree of washing was gradually intensified in each round.
- the input and output of phage counts for each round were calculated as dilution and CFU (Fig. 2A).
- the AbS0 Fab phage showed the highest antigen-binding ability to the Bio-PreS1-L peptide, and also showed a high binding ability to the preS1 (1-119) antigen of Example 1 (Fig. 2C) .
- AbSO Fab was converted to human IgG1 and expressed in HEK293F cells, and protein purification was performed on the culture supernatant.
- VH and VK sequences were amplified by PCR, and then combined with IgG heavy chain and light chain leader sequences, respectively, using recombinant PCR.
- the resulting VH and VK sequences were subcloned into the Eco RI- Apa I and HindIII- Bsi WI sites of the pdCMV- dhfr C expression plasmid containing human C ⁇ 1 and C ⁇ genes to construct the pdCMV- dhfr C-AbS0 expression plasmid. .
- the expression plasmid prepared in 3-1 was introduced into 30 mL of HEK293F cells at a ratio of 1:4 (30 ⁇ g:120 ⁇ g) using polyethyleneimine (PEI).
- PEI polyethyleneimine
- the transformed cells were cultured for 7 days, affinity chromatography was performed using Protein A in the culture supernatant, the concentration of the antibody was determined using a UV-Vis spectrophotometer, and the purity of the antibody purified for SDS-PAGE was determined. verified (Fig. 3A).
- each well was coated with GST-preS1 (1-56)-strep (30 nM/well) of genotypes A-D (Fig. 1). Then, it was reacted with serially diluted AbSO antibody. Bound AbSO antibody was detected using anti-human IgG Fc-HRP (1:10,000 v/v, Jackson) as a secondary antibody.
- the affinity of the antibody was determined by Bio-Layer Interferometry using Octet RED384 (ForteBio). Specifically, anti-human Fc-coated biosensor tips (AHC, ForteBio) were activated by stirring a 96-well microtiter plate (Greiner Bio-One) at 1000 rpm for 20 minutes in 0.1% PBA (0.1% BSA in PBS). . AbSO antibody (1 ⁇ g/ml, 200 ⁇ l) was added, captured for 10 minutes, and washed with 0.1% PBA for 2 minutes.
- GST-preS1(1-56)-strep antigen of HBV genotype A was subjected to 2-fold serial dilution (25, 12.5, 6.25, 3.125, 1.5625 nM) with 0.1% PBA, followed by assotiation with the antibody bound to the tip for 5 minutes, respectively. step and dissociation step was performed for 10 minutes. For baseline drift, the measured value was corrected by subtracting the value of the control sensor (antibody-captured AHC sensor) exposed only to the running buffer without antibody. The operating temperature was maintained at 30°C. Data were analyzed using ForteBio data analysis software version 7.1 using a 1:1 interaction model (fitting global, Rmax unlinked by sensor).
- the affinity of the AbSO antibody was 0.5 nM.
- the human ovarian cancer cell line SKOV3 expressing L1CAM but not preS1 was used to perform flow cytometry.
- the AbS0 antibody specifically binds to the preS1 antigen.
- Immunoprecipitation assay was performed using HBV genotype D to confirm whether AbSO antibody binds to HBV virions.
- Anti-preS1 humanized antibody HzKR127-3.2 which exhibits conventional HBV-neutralizing efficacy, was used as a positive control for HBV genotype D, and mouse IgG was used as a negative control. After immunoprecipitation, viral DNA was extracted and measured by Southern blotting.
- HBV particles of HBV genotype D HepG2 cells were seeded in a 6-well plate at a density of 6 ⁇ 10 5 and cultured at 37°C. The next day, HepG2 cells were transfected with pHBV1.2 (HBV genotype D) and incubated for 4 days. The culture supernatant was harvested and incubated with 1 ⁇ g/ml of AbS0, HzKR127-3.2 (positive control), or mouse IgG (negative control) overnight at 4°C, followed by immunoprecipitation with 20 ⁇ l of protein A beads at 4°C for 6 hours. was performed. After the immunoprecipitated complex was washed three times with PBS, viral DNA was detected as follows.
- the immunocomplexes were treated with DNase I (Sigma) and mung bean nuclease (Takara, Kusatsu, Shiga, Japan) at 37°C for 20 minutes.
- DNase I Sigma
- mung bean nuclease Takara, Kusatsu, Shiga, Japan
- HBV DNA was extracted and purified using ethanol and 3M sodium acetate. Purified DNA was separated on a 1% agarose gel and HBV DNA was detected by Southern blotting.
- HBV particles of genotype D were pre-incubated with different concentrations of antibody and added to HepG2-NTCP cells overexpressing the cellular receptor NTCP.
- HepG2-NTCP HepG2 cell line overexpressing NTCP.
- HepG2-NTCP cells were seeded in a 6-well plate at a density of 6 ⁇ 10 5 and cultured at 37°C. The next day, HepG2-NTCP cells were infected with HBV particles of genotype D ( ⁇ 2000 viral genome equivalents per cell) in primary hepatocyte maintenance medium (PMM) medium containing 4% polyethylene glycol (PEG) and 2.5% DMSO.
- PMM primary hepatocyte maintenance medium
- PEG polyethylene glycol
- HBV particles were pre-incubated with diluted AbS0 antibody (10, 1, 0.1 ⁇ g) or mouse IgG (10 ⁇ g) for 1 hour at room temperature, respectively, and then added to cultured HepG2-NTCP cells, followed by 2.5 Cells were cultured for 7 days, replacing every 2 hours with PMM medium containing % DMSO. Intracellular HBV DNA was extracted from infected HepG2-NTCP cells and Southern blotting was performed.
- AbS0 has the ability to neutralize HBV infection.
- the novel antibody of the present invention can bind to both HBV genotypes A-D and can effectively neutralize viruses of the genotype, preventing viral infection of the genotype or causing viral infection. This suggests that it is effective in treating hepatitis patients. In addition, this suggests that the HBV genotype A-D infection can also be specifically detected.
- the light chain variable region of the novel antibody AbS0 of the present invention is shown in SEQ ID NO: 14, and the heavy chain variable region is shown in SEQ ID NO: 15.
- DNA in which each residue of preS1 (19-34) is substituted with alanine is synthesized by recombinant PCR using a primer containing a mutant sequence, digested with BamHI and EcoRI (NEB) restriction enzymes, and wild type
- BamHI and EcoRI (NEB) restriction enzymes By subcloning each of the pGST-preS1(1-56)-strep expression plasmid containing the preS1 sequence into the BamHI-EcoRI site, an expression plasmid having an alanine substitution mutant instead of the wild type preS1(1-56) was constructed. Thereafter, in order to express each variant, the recombinant E. coli DH5 ⁇ was cultured for 19 hours at 18° C. in a medium containing 0.2 mM IPTG.
- the cells were disrupted by sonication, and the GST-preS1(1-56)-strep protein was purified by affinity chromatography using glutathione beads (Genscript), and the purity of the purified protein was determined by 12% SDS-PAGE. It was confirmed (FIG. 5).
- the antigen-binding ability of the AbSO antibody for each alanine substitution variant was analyzed by indirect ELISA (FIG. 6).
- each well was coated with mutated GST-preS1(1-56)-strep antigen (200 ng) and then incubated with serially diluted AbSO antibody. Bound AbSO antibody was detected using anti-human IgG Fc-HRP (1:10,000 v/v, Thermo) as a secondary antibody.
- Example 6 Determination of epitope binding site (paratope) of AbSO antibody and identification of variants with increased affinity
- VH or VL genes were synthesized using a recombinant PCR method using primers containing mutant sequences.
- each synthesized VH gene was digested with Eco RI and Apa I restriction enzymes, and then subcloned at the Eco RI -Apa I site of the expression vector (pCMV-dhfr-AbS0H) containing the heavy chain gene of AbS0 antibody
- each synthesized VL gene was digested with HindIII and BsiWI restriction enzymes, and then HindIII-BsiWI of the expression vector (pCMV-dhfr- AbS0k ) containing the AbS0 antibody light chain gene.
- the constructed expression plasmid was mixed with polyethyleneimine (PEI) at a ratio of 1:4 (30 ⁇ g:120 ⁇ g) and introduced into HEK293F cells. After culturing the transformed cells for 7 days to express the mutant antibody, the culture supernatant was obtained and their antigen-binding ability was analyzed by indirect ELISA. Specifically, each well was coated with recombinant GST-preS1(1-56)-strep antigen (100 ng) of HBV genotype C, and then serially diluted AbS0 antibody or AbS0 variant was conjugated and anti-human as a secondary antibody. IgG Fc-HRP (1:10,000 v/v, Thermo) was added and reacted.
- PEI polyethyleneimine
- the concentration of AbS0 antibody or AbS0 variant used in indirect ELISA was determined by quantitative ELISA. After coating each well with anti-human IgG kappa antibody (100 ng, Thermo), serially diluted AbSO antibodies or variants were bound, and as a secondary antibody, anti-human IgG Fc-HRP (1:10,000 v/v, Thermo) was added to react.
- HCDR3 variant L100A and LCDR3 variant Y96A have no or very low antigen-binding activity, whereas the other 6 variants (V95A, S99A of HCDR3; S91A, Y92A, S93A, S94A of LCDR3) have the same antigen as wild type AbS0. binding capacity was shown (FIG. 7).
- CDR3 variants I96A and Y97A were not expressed and could not be analyzed. From this result, it was confirmed that Leu100 of HCDR3 of AbS0 and Tyr96 of LCDR3 are very important in antigen binding.
- amino acids 33 of HCDR1 and 50 amino acids of HCDR2 in antibodies vary widely from antibody to antibody and are known to be involved in antigen binding. Therefore, in the case of AbS0 antibodies, to analyze whether residues 33 and 50 are involved in antigen binding Site-directed mutagenesis was performed for (Positions 33 and 50 are positions described based on SEQ ID NO: 15)
- amino acid 33 of HCDR1 is alanine.
- alanine was converted to 8 different residues (S, P, V, T, G, D, L, N). Since amino acid number 50 is serine, it was substituted with 6 other residues (A, Y, E, F, V, P).
- mutant gene recombinant PCR was performed using degenerate primers, and the synthesized VH gene was digested with Eco RI and Apa I restriction enzymes, and then subcloned at the Eco RI -Apa I site of pdCMV-dhfr-AbS0 to express variants Plasmids were obtained, and through sequencing, it was confirmed that a total of 14 variants were secured.
- Each expression plasmid was introduced into HEK293F cells by the same method as in 6-1 above, and the culture supernatant obtained after culturing for 7 days was analyzed by indirect ELISA and quantitative ELISA as in 6-1 above.
- the S50A variant showed slightly increased antigen-binding ability compared to the AbS0 antibody, and the antigen-binding activity of the S50Y variant was greatly reduced, while the S50F and S50E variants did not show antigen-binding activity ( Figure 8D).
- the S50V and S50P variants expression was not detected, so antigen binding ability could not be analyzed. This result means that residue 50 of HCDR2 plays an important role in antigen binding, and alanine is more optimal for antigen binding than serine.
- Example 6-2 the recombinant GST-preS1(1-56)-strep antigen of HBV genotype C was used to analyze the antigen-binding ability of the AbS0 antibody and its variants. In order to analyze whether the binding capacity is higher, indirect ELISA was performed on the recombinant GST-preS1(1-56)-strep antigen of genotype A. As a result, it was confirmed that AbS1 showed a higher antigen binding ability to preS1 of genotype A than AbS0 (FIG. 9).
- the epitope of the AbS1 antibody (Leu22, Gly23, Phe25 of preS1) is contained within the HBV receptor-binding motif, in order to estimate whether the AbS1 antibody can broadly bind to HBV present on earth, the HBV database (https://hbvdb.
- the HBV database https://hbvdb.
- 96.6% of the preS1 sequences had NPLGFFP sequence as a receptor-binding motif, and 2.6% had NPLGFLP with leucine instead of phenylalanine at position 25 (Table 3).
- genotypes E and F Quantitative ELISA (FIG. 10A) and indirect ELISA (FIG. 10B) were performed on the recombinant GST-preS1(1-56)-strep antigen.
- the F25A mutant preS1 antigen of genotype C of Example 5 was used as a negative control.
- AbS1 binds well to preS1 of genotypes E and F (FIG. 10).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Antibody | KD | Kon (1/Ms) | Kdis (1/s) | Full R2 |
AbS0 | 0.50 nM | 3.92 x 105 | 1.94 x 10-4 | 0.9969 |
L3-v1 | S91A | H3-v1 | V95A |
L3-v2 | Y92A | H3-v2 | I96A |
L3-v3 | S93A | H3-v3 | Y97A |
L3-v4 | S94A | H3-v4 | S99A |
L3-v5 | Y96A | H3-v5 | L100A |
Receptor-binding motif
(number) |
Genotype | |||||||
A | B | C | D | E | F | G | H | |
NPLGFFP (9312) |
1355 (96.50%) |
2751 (98.18%) |
3055 (97.73%) |
1453 (99.18%) |
432 (96.86%) |
234 (81.53%) |
1 (1.28%) |
31 (100%) |
NPLGFLP(247) | 36 (2.56%) |
30 (1.07%) |
38 (1.22%) |
8 (0.55%) |
5 (1.12%) |
53 (12.47%) |
77 (98.72%) |
0 (0.00%) |
Others(80) | 13(9 D.S.*) (0.93%) |
21(12 D.S.) (0.75%) |
33(18 D.S.) (1.06%) |
4(3 D.S.) (0.27%) |
9(8 D.S.) (2.02%) |
0 (0.00%) |
0 (0.00%) |
0 (0.00%) |
Total(9639) | 1404 | 2802 | 3126 | 1465 | 446 | 287 | 78 | 31 |
Claims (20)
- HBV(Hepatitis B virus)의 preS1 항원 내의 특정 위치의 아미노산에 결합하는 항체로,상기 preS1 항원 내의 특정 위치는 서열번호 19를 기준으로 22번, 23번 및 25번 위치에 상응하는 것인, 항체.
- 제1항에 있어서, 상기 항체는 서열번호 5의 LCDR3 서열의 8번 타이로신 및 서열번호 9의 HCDR3 서열의 6번 류신을 파라토프로 갖는 것인, 항체.
- 제1항에 있어서, 상기 항체는 서열번호 8로 표시되는 HCDR2 서열의 1번 아미노산을 파라토프로 갖는 것인, 항체.
- 제3항에 있어서, 상기 서열번호 8로 표시되는 HCDR2 서열의 1번 아미노산은 알라닌 또는 세린인 것인, 항체.
- 제1항에 있어서, 상기 항체는(a) 서열번호 3의 경쇄 CDR1, 서열번호 4의 경쇄 CDR2, 및 서열번호 5의 경쇄 CDR3을 포함하는 경쇄 가변영역; 및(b) 서열번호 7의 중쇄 CDR1, 서열번호 8의 중쇄 CDR2, 및 서열번호 9의 중쇄 CDR3을 포함하는 중쇄 가변영역;을 포함하는 것인, 항체.
- 제1항에 있어서, 상기 항체는(a) 서열번호 3의 경쇄 CDR1, 서열번호 4의 경쇄 CDR2, 및 서열번호 6의 경쇄 CDR3을 포함하는 경쇄 가변영역; 및(b) 서열번호 10의 중쇄 CDR1, 서열번호 11 또는 12의 중쇄 CDR2, 및 서열번호 13의 중쇄 CDR3을 포함하는 중쇄 가변영역;을 포함하는 것인, 항체.
- 제1항에 있어서, 상기 항체는 HBV의 유전자형 A, B, C, D, E 및 F에서 선택된 하나 이상의 유전자형에 특이적으로 결합하는 것인 항체.
- 제1항에 있어서, 상기 항체의 경쇄 가변영역은 서열번호 1로 구성되는 것인, 항체.
- 제1항에 있어서, 상기 항체의 중쇄 가변영역은 서열번호 2로 구성되는 것인, 항체.
- 제1항에 있어서, 상기 항체는 서열번호 14로 기재된 경쇄 가변영역; 및 서열번호 15 또는 16으로 기재된 중쇄 가변영역을 포함하는 것인, 항체.
- 제1항 내지 제10항 중 어느 한 항의 항체를 코딩하는 폴리뉴클레오타이드.
- 제11항의 폴리뉴클레오타이드를 포함하는 발현 벡터.
- 제12항의 발현 벡터를 포함하는, 숙주세포.
- 제1항 내지 제10항 중 어느 한 항의 항체를 포함하는, HBV 감염에 대한 예방 또는 치료용 약학적 조성물.
- 제14항에 있어서, 상기 조성물은 B형 간염의 예방 또는 치료를 위한 것인, 조성물.
- 제1항 내지 제10항 중 어느 한 항의 항체를 이용하여, HBV 감염 의심 개체로부터 분리된 생물학적 시료에 존재하는 preS1 단백질을 항원-항체 반응을 통하여 검출하는 단계를 포함하는, HBV감염의 진단 방법.
- 제12항에 있어서, 상기 방법은 B형 간염의 진단을 하기 위한 것인, 방법.
- 제1항 내지 제10항 중 어느 한 항의 항체를 포함하는, HBV 검출용 조성물.
- 제18항에 있어서, 상기 조성물은 B형 간염 진단용인 것인 조성물.
- 제18항의 조성물을 포함하는, HBV검출용 키트.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280056403.0A CN117858896A (zh) | 2021-06-15 | 2022-05-30 | 特异性结合乙型肝炎病毒preS1抗原肝细胞受体结合基序的人抗体及其用途 |
EP22825190.6A EP4357360A1 (en) | 2021-06-15 | 2022-05-30 | Human antibody specifically binding to binding site of hepatocyte receptor of hepatitis b virus pres1 antigen, and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210077615 | 2021-06-15 | ||
KR10-2021-0077615 | 2021-06-15 | ||
KR10-2021-0093625 | 2021-07-16 | ||
KR20210093625 | 2021-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022265264A1 true WO2022265264A1 (ko) | 2022-12-22 |
Family
ID=84527149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/007679 WO2022265264A1 (ko) | 2021-06-15 | 2022-05-30 | B형 간염바이러스 pres1항원의 간세포 수용체 결합부위에 특이적으로 결합하는 인간 항체 및 이의 용도 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4357360A1 (ko) |
KR (2) | KR20220168148A (ko) |
WO (1) | WO2022265264A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180009780A (ko) * | 2015-05-22 | 2018-01-29 | 화후이 헬스 리미티드 | 항-Pre-S1 HBV 항체 |
KR20180012245A (ko) * | 2015-03-25 | 2018-02-05 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도 |
US20180354993A1 (en) * | 2015-12-16 | 2018-12-13 | Ruprecht-Karls-Universität Heidelberg | Cyclic ntcp-targeting peptides and their uses as entry inhibitors |
KR20200092539A (ko) * | 2019-01-25 | 2020-08-04 | 진원생명과학 주식회사 | B형 간염 치료 및 예방용 항체 |
US20200345838A1 (en) * | 2017-11-16 | 2020-11-05 | University Of Washington | A Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein |
-
2022
- 2022-05-30 EP EP22825190.6A patent/EP4357360A1/en active Pending
- 2022-05-30 KR KR1020220066283A patent/KR20220168148A/ko not_active Application Discontinuation
- 2022-05-30 WO PCT/KR2022/007679 patent/WO2022265264A1/ko active Application Filing
-
2024
- 2024-02-20 KR KR1020240024423A patent/KR20240029010A/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180012245A (ko) * | 2015-03-25 | 2018-02-05 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도 |
KR20180009780A (ko) * | 2015-05-22 | 2018-01-29 | 화후이 헬스 리미티드 | 항-Pre-S1 HBV 항체 |
US20180354993A1 (en) * | 2015-12-16 | 2018-12-13 | Ruprecht-Karls-Universität Heidelberg | Cyclic ntcp-targeting peptides and their uses as entry inhibitors |
US20200345838A1 (en) * | 2017-11-16 | 2020-11-05 | University Of Washington | A Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein |
KR20200092539A (ko) * | 2019-01-25 | 2020-08-04 | 진원생명과학 주식회사 | B형 간염 치료 및 예방용 항체 |
Non-Patent Citations (12)
Title |
---|
BARBAS ET AL., METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, vol. 2, 1991, pages 119 |
CHO S. ET AL., MABS, vol. 8, no. 2, 2016, pages 414 - 425 |
HEERMANN KGOLDMANN USCHWARTZ WSEYFFARTH TBAUMGARTEN HGERLICH W: "Large surface proteins of hepatitis B virus containing the pre-s sequence", JOURNAL OF VIROLOGY, vol. 52, 1984, pages 396 - 402, XP001053577 |
J. VIROL., vol. 75, no. 14, July 2001 (2001-07-01), pages 6692 - 9 |
KIM HSHONG HJ, BIOTECHNOLOGY LETTERS., vol. 17, 1995, pages 871 - 876 |
KIM JH ET AL.: "Enhanced humanization and affinity maturation of neutralizing anti-hepatitis B virus preS1 antibody based on antigen-antibody complex structure", FEBS LETT., vol. 589, pages 193 - 200, XP029125564, DOI: 10.1016/j.febslet.2014.11.046 |
KIM JHGRIPON PBOUEZZEDINE FJEONG MSCHI SWRYU SEHONG HJ: "Enhanced humanization and affinity maturation of neutralizing anti-hepatitis B virus preS1 antibody based on antigen-antibody complex structure", FEBS LETTERS., vol. 589, 2015, pages 193 - 200, XP029125564, DOI: 10.1016/j.febslet.2014.11.046 |
KOEHERMILSTEIN, NATURE, vol. 256, 1976, pages 495 |
MIN, J.-K. ET AL., CLIN. CANCER RES., vol. 16, no. 14, 2010, pages 3571 - 80 |
PIZARRO JCVULLIEZ-LE NORMAND BRIOTTOT M-MBUDKOWSKA ABENTLEY GA: "Structural and functional characterization of a monoclonal antibody specific for the preS1 region of hepatitis B virus", FEBS LETTERS, vol. 509, 2001, pages 463 - 468, XP071243294, DOI: 10.1016/S0014-5793(01)03190-8 |
WI JJEONG MSHONG HJ: "Construction and characterization of an anti-hepatitis B virus preS1 humanized antibody that binds to the essential receptor binding site", JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, vol. 27, 2017, pages 1336 - 1344 |
WINTER ET AL., ANN. REV. IMMUNOL., vol. 12, 1994, pages 433 |
Also Published As
Publication number | Publication date |
---|---|
KR20240029010A (ko) | 2024-03-05 |
KR20220168148A (ko) | 2022-12-22 |
EP4357360A1 (en) | 2024-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019098682A1 (ko) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 | |
CA2936565C (en) | Anti-jagged1 antibodies and methods of use | |
AU2007334366B2 (en) | Human antibodies to human delta like ligand 4 | |
JP2022106950A (ja) | モノクローナル抗IL-1RAcP抗体 | |
US9541004B2 (en) | Antagonist antibodies against EphB3 | |
WO2014119969A1 (ko) | 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법 | |
US20140286936A1 (en) | Anti-human cxcr4 antibodies | |
WO2014077648A1 (ko) | 인간 및 마우스 l1cam 단백질에 특이적으로 결합하는 항체 및 이의 용도 | |
WO2016085289A1 (ko) | B형 간염 바이러스의 pres1에 특이적으로 결합하는 항체 및 이의 용도 | |
KR20200128544A (ko) | Pd1 결합제 | |
WO2020101365A1 (ko) | 안정성이 향상된 항 c-met 항체 또는 그의 항원 결합 단편 | |
KR20210141988A (ko) | C5ar을 표적으로 하는 항체 | |
WO2022085905A1 (ko) | SARS-CoV-2 스파이크 단백질에 특이적으로 결합하는 항체 및 이의 용도 | |
WO2022265264A1 (ko) | B형 간염바이러스 pres1항원의 간세포 수용체 결합부위에 특이적으로 결합하는 인간 항체 및 이의 용도 | |
US20150010542A1 (en) | Antibodies to toso | |
WO2020116963A1 (ko) | 엔도텔린 수용체 a 활성 조절 항체 | |
WO2020004934A1 (ko) | 항-bcma 항체 및 그 용도 | |
WO2023038477A1 (ko) | 코로나바이러스 뉴클레오캡시드 단백질에 특이적인 항체 및 이의 용도 | |
JP2023052664A (ja) | 抗配列類似性19を持つファミリー、メンバーa5抗体及びその使用方法 | |
WO2014021693A2 (ko) | Tm4sf5 단백질에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 | |
JP2022550121A (ja) | Lifに特異的な結合分子及びその使用 | |
WO2020250204A1 (ko) | 신규 cthrc1에 특이적 항체 및 이의 용도 | |
WO2022098173A1 (ko) | 코로나바이러스 스파이크 단백질에 특이적인 항체 및 이의 용도 | |
WO2017142294A1 (ko) | EGFRvIII에 대한 항체 및 이의 용도 | |
WO2020205477A1 (en) | ANTI-POLYMERIC IgA ANTIBODIES AND METHODS OF USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22825190 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023577967 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022825190 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022825190 Country of ref document: EP Effective date: 20240115 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280056403.0 Country of ref document: CN |